Related Experiment Video
Updated: Jan 22, 2026

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
Published on: October 13, 2023
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
V Shobha1, A M Desai, T Matthew
1Department of Clinical Immunology and Rheumatology, St. John's National Academy of Health Sciences, Bengaluru. vineeta_shobha@yahoo.co.in.
Abstract:
Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Acute Coronary Syndrome V: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management

